TABLE 3.
Cochran‐Mantel‐Haenszel statistics for the primary endpoint successful completion of the study without increase in furosemide dose for the entire full analysis set (FAS) population and the FAS population divided into strata
| Treatment group | N‐1 | N‐2 | Odds ratio | 95% CI | |
|---|---|---|---|---|---|
| All | Pimobendan | 39 | 12 | 0.855 | 0.33‐2.22 |
| Placebo | 37 | 13 | |||
| LVOTO | Pimobendan | 14 | 4 | 0.267 | 0.06‐1.26 |
| Placebo | 15 | 9 | |||
| No LVOTO | Pimobendan | 25 | 8 | 2.118 | 0.54‐8.34 |
| Placebo | 22 | 4 |
Notes: There was no statistical difference between treatments in each group (P > .05).
Abbreviations: CI, confidence interval; LVOTO, left ventricular outflow tract obstruction; N‐1, all cats; N‐2, cats that reached the primary endpoint of successful outcome at D180.